Research Use Only (RUO). This article is for education and shares what published science says about a research compound. It is not medical advice, and nothing here is a suggestion to use any peptide on people or animals.
If you searched retatrutide clinical trials, retatrutide phase 3, or retatrutide trial sign up, this is an overview of the trial program and what it has shown. This is educational information; retatrutide is Research Use Only and not approved.
The Phase 2 trial
Retatrutide's Phase 2 obesity trial was published in the New England Journal of Medicine. It studied once-weekly amounts of 1, 4, 8, and 12 mg and reported mean weight reductions of up to 24.2% at 48 weeks. This trial set the stage for the larger Phase 3 program.
The Phase 3 TRIUMPH program
TRIUMPH is the name of retatrutide's Phase 3 program run by Eli Lilly. It includes multiple trials across obesity and type 2 diabetes. Reported results include up to about 30.3% average weight loss in TRIUMPH-1 and 28.7% at 12 mg over 68 weeks in a trial that also studied knee osteoarthritis. Lilly has said additional Phase 3 trials should complete in 2026.
How do clinical trials work?
Trials move in phases. Phase 2 tests different amounts and looks for early signals; Phase 3 tests the compound in larger groups to confirm results and watch safety. Only after these steps can a company ask the FDA to review a compound for approval.
About trial sign-ups
Official retatrutide trials are run by the manufacturer and research sites, not by supplement or research-chemical sellers. People interested in real studies can look at official registries and sponsor listings. Buying a research compound is not the same as joining a clinical trial.
Retatrutide research materials at Dissolv Labs
Dissolv Labs supplies high-purity compounds as reference materials for laboratory research only. They are not for human or animal use.
Frequently asked questions
What phase is retatrutide in?
Phase 3. Its TRIUMPH program is running, with more trials due to complete in 2026.
How do I sign up for a retatrutide trial?
Official trials are listed through the sponsor and public trial registries, not through peptide sellers.
Did the trials work?
Reported Phase 3 results showed large mean weight reductions, but the compound is still under review and not approved.
The bottom line
Retatrutide has cleared Phase 2 and posted strong Phase 3 TRIUMPH results, with more data expected in 2026. It remains investigational and is sold only as a Research Use Only reference material.
Sources
- Jastreboff et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (NEJM, via PubMed)
- Eli Lilly: Retatrutide Phase 3 (TRIUMPH) topline results
- AJMC: Retatrutide achieves up to 30.3% average weight loss in Phase 3 TRIUMPH-1
- Drugs.com: Retatrutide history and FDA approval status
Disclaimer: All Dissolv Labs products are sold for Research Use Only and are not for human or veterinary use. This content is educational and is not medical advice, diagnosis, treatment guidance, or a recommendation to consume any substance.
